China Resources Pharmaceutical: Achieve total revenue of 269.574 billion yuan by 2025, completing multiple acquisition projects in biopharmaceuticals, traditional Chinese medicine, chemical drugs, and other fields.

On March 25, China Resources Pharmaceutical announced its performance report for the year ending December 31, 2025. The company achieved total revenue of 269.574 billion yuan, an increase of 4.6% from 257.673 billion yuan the previous year. Gross profit was 44.508 billion yuan, up 9.4% from 40.689 billion yuan last year, with an overall gross profit margin rising to 16.5%. Net profit was 9.653 billion yuan, a growth of 14.9% compared to 8.403 billion yuan in 2024; the profit attributable to equity holders of the company was 4.045 billion yuan, an increase of 20.7%.

During the reporting period, the group completed multiple merger and acquisition projects in the fields of biopharmaceuticals, traditional Chinese medicine, and chemical pharmaceuticals, introduced several high-quality products, established an industrial development fund, and further enriched investment methods; in terms of technological innovation, it promoted the launch of new products, strengthened external cooperation, advanced several innovative coalitions, and optimized the product mix and business structure; in operational management, it focused on building an excellent operational system, continuously promoted cost reduction and efficiency enhancement, and improved digital intelligence capabilities, winning multiple industry honors; in supply chain construction, it strengthened upstream and downstream collaborative control, with supply chain resilience and overall competitiveness continuously enhanced; in international expansion, it achieved multi-variety and multi-country registered sales, further enhancing the influence of traditional Chinese medicine culture.

(China Resources Pharmaceutical Announcement)

(Editor: Yang Yan Lin Chen)

Keywords:

                                                            Healthcare